Your browser doesn't support javascript.
loading
Pharmacokinetics and Safety of a Raltegravir-Containing Regimen in Children Aged 4 Weeks to 2 Years Living With Human Immunodeficiency Virus and Receiving Rifampin for Tuberculosis.
Krogstad, Paul; Samson, Pearl; Acosta, Edward P; Moye, Jack; Townley, Ellen; Bradford, Sarah; Brown, Emily; Denson, Kayla; Graham, Bobbie; Hovind, Laura; Sise, Thucuma; Teppler, Hedy; Mathiba, Sisinyana Ruth; Fairlie, Lee; Winckler, Jana L; Slade, Gretchen; Meyers, Tammy.
Afiliação
  • Krogstad P; Departments of Pediatrics and Molecular and Medical Pharmacology, David Geffen School of Medicine at Los Angeles, Los Angeles, California, USA.
  • Samson P; Statistical and Data Management Center, Frontier Science Foundation/Harvard T.H. Chan School of Public Health Boston, Massachusetts, USA.
  • Acosta EP; Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • Moye J; Maternal and Pediatric Infectious Disease Branch, Division of Extramural Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Maryland, USA.
  • Townley E; Columbus Technologies and Services, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA.
  • Bradford S; FHI360, Durham, North Carolina, USA.
  • Brown E; FHI360, Durham, North Carolina, USA.
  • Denson K; Frontier Science Foundation, Inc, Amherst, New York, USA.
  • Graham B; Frontier Science Foundation, Inc, Amherst, New York, USA.
  • Hovind L; Frontier Science Foundation, Inc, Amherst, New York, USA.
  • Sise T; Columbus Technologies and Services, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA.
  • Teppler H; Global Clinical Development - Infectious Diseases, Merck & Co, Inc, Kenilworth, New Jersey, USA.
  • Mathiba SR; Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa.
  • Fairlie L; Wits Reproductive Health and HIV Institute, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
  • Winckler JL; Desmond Tutu TB Centre, Department of Paediatrics, Stellenbosch University, Cape Town South Africa.
  • Slade G; Department of Paediatrics and Child Health, Family Clinical Research Unit, Stellenbosch University, Cape Town, South Africa.
  • Meyers T; Department of Paediatrics, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
J Pediatric Infect Dis Soc ; 10(2): 201-204, 2021 Mar 26.
Article em En | MEDLINE | ID: mdl-32448902
ABSTRACT
Pharmacological interactions limit treatment options for children living with human immunodeficiency virus (HIV) and tuberculosis (TB). We found that 12 mg/kg twice daily raltegravir chewable tablets (administered after crushing) safely achieved pharmacokinetic targets in children living with HIV aged 4 weeks to <2 years receiving concurrent rifampin to treat TB. CLINICAL TRIALS REGISTRATION NCT01751568.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Tuberculose / Infecções por HIV / Fármacos Anti-HIV Limite: Child / Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Tuberculose / Infecções por HIV / Fármacos Anti-HIV Limite: Child / Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article